Not for human consumption, veterinary use, or clinical administration. Sold exclusively to qualified laboratories and researchers for in-vitro study.
Melanotan-II (MT-2) is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), designed with structural modifications that increase its binding affinity at melanocortin receptors compared to the native peptide. It acts on multiple melanocortin-receptor subtypes — including MC1R, MC3R, MC4R and MC5R — making it a useful pharmacological probe in receptor-biology research.
Research has explored Melanotan-II as a tool for investigating melanocortin-receptor pharmacology, including binding kinetics, receptor selectivity, and downstream intracellular signalling cascades such as cAMP-pathway activation. Studies using MT-2 have helped characterize the functional roles of individual melanocortin-receptor subtypes in pre-clinical models, contributing to a broader understanding of the melanocortin system.
Researchers have also studied Melanotan-II in models examining neuroendocrine signalling and autonomic nervous system regulation, where MC4R plays a documented role. Its broad receptor-activity profile has made it a frequently cited reference compound in the melanocortin-peptide pharmacology literature.
myPEPT supplies Melanotan-II at verified purity with a Certificate of Analysis from independent third-party lab testing. Lyophilized and shipped across the EU in properly sealed research vials.
What researchers should know: Melanotan-II (MT-2) is supplied strictly for laboratory research use only — it is not for human consumption or injection. It is not approved for human use and is not a therapeutic or cosmetic product in this format. Handle and store it in accordance with your institution's protocols and all applicable regulations governing research peptides.
For research use only. This product is intended exclusively for in-vitro research and laboratory applications. Not approved for human or animal consumption, medical treatment, or therapeutic use.


